The GENIE BPC NSCLC cohort: A real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Journal Article
| Authors: | Choudhury, N. J.; Lavery, J. A.; Brown, S.; de Bruijn, I.; Jee, J.; Tran, T. N.; Rizvi, H.; Arbour, K. C.; Whiting, K.; Shen, R.; Hellmann, M.; Bedard, P. L.; Yu, C.; Leighl, N.; LeNoue-Newton, M.; Micheel, C.; Warner, J. L.; Ginsberg, M. S.; Plodkowski, A.; Girshman, J.; Sawan, P.; Pillai, S.; Sweeney, S. M.; Kehl, K. L.; Panageas, K. S.; Schultz, N.; Schrag, D.; Riely, G. J.; on behalf of the AACR GENIE BPC Core Team |
| Article Title: | The GENIE BPC NSCLC cohort: A real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer |
| Abstract: | Purpose: We describe the clinical and genomic landscape of the non-small cell lung cancer (NSCLC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Experimental Design: A total of 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions participating in AACR GENIE were randomly chosen for curation using the PRISSMM data model. Progression-free survival (PFS) and overall survival (OS) were estimated for patients treated with standard therapies. Results: In this cohort, 44% of tumors harbored a targetable oncogenic alteration, with EGFR (20%), KRAS G12C (13%), and oncogenic fusions (ALK, RET, and ROS1; 5%) as the most frequent. Median OS (mOS) on first-line platinum-based therapy without immunotherapy was 17.4 months [95% confidence interval (CI), 14.9-19.5 months]. For second-line therapies, mOS was 9.2 months (95% CI, 7.5-11.3 months) for immune checkpoint inhibitors (ICI) and 6.4 months (95% CI, 5.1-8.1 months) for docetaxel - ramucirumab. In a subset of patients treated with ICI in the second-line or later setting, median RECIST PFS (2.5 months; 95% CI, 2.2-2.8) and median real-world PFS based on imaging reports (2.2 months; 95% CI, 1.7-2.6) were similar. In exploratory analysis of the impact of tumor mutational burden (TMB) on survival on ICI treatment in the second-line or higher setting, TMB z-score harmonized across gene panels was associated with improved OS (univariable HR, 0.85; P = 0.03; n = 247 patients). Conclusions: The GENIE BPC cohort provides comprehensive clinicogenomic data for patients with NSCLC, which can improve understanding of real-world patient outcomes. © 2023 The Authors. |
| Keywords: | genetics; proto-oncogene proteins; carcinoma, non-small-cell lung; lung neoplasms; pathology; protein tyrosine kinase; lung tumor; genomics; protein-tyrosine kinases; non small cell lung cancer; humans; human; immunological antineoplastic agent; antineoplastic agents, immunological; proto oncogene protein |
| Journal Title: | Clinical Cancer Research |
| Volume: | 29 |
| Issue: | 17 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2023-09-01 |
| Start Page: | 3418 |
| End Page: | 3428 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-23-0580 |
| PUBMED: | 37223888 |
| PROVIDER: | scopus |
| PMCID: | PMC10472103 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work